Novo Nordisk

Change is in the air for the Indian clinical trial market. The rapid approval of COVID-19 vaccinations during the SARS-CoV-2 pandemic illustrated the value of clinical studies that could improve therapeutic regimens, and advance evidence-based medicine. With the use of artificial intelligence (AI) thrown in the mix, the…

Diabeloop SA reported a partnership with Novo Nordisk A/S. The med-tech is planning to integrate DBL-4pen, its self-learning algorithm for multiple daily injection therapy, into Novo Nordisk's connected, reusable insulin pens: Novopen and Novopen Echo Plus. “Our partnership is designed to deliver more automated solutions to people with diabetes, optimizing outcomes and improving quality of…

Artificial intelligence (AI) stocks are gaining attention, with Marvell Technology (MRVL), Arista Networks (ANET), and Synopsys (SNPS) leading the way. Marvell produces chips used in various industries such as wireless phone networks, automobiles, and data centers. The company expects its AI chip business to grow significantly in the coming years. On July 11, KeyBanc raised…

In September, Novo Nordisk signed a strategic partnership with Microsoft to utilise big data and AI to facilitate drug discovery and development. Image Credit: SuperOhMo / Shutterstock. …

Following is a summary of current health news briefs. Nvidia deepens bets on AI in drug discovery with Recursion investment Chip designer Nvidia will invest $50 million to speed up training of Recursion's artificial intelligence models for drug discovery, the companies said on Wednesday, sending the biotech firm's shares surging about…

By Meena Villa Vij, Vice President, Digital, Data & IT, Novo Nordisk Global Business Services and Francis Prashanth Anandan, Lead, Digital Innovation Hub, India, Novo Nordisk Global Business Services The pharmaceutical industry has been on an accelerated path to scientific advancement. A human-centric approach to drug discovery combined with core competencies and technology platforms drive…

Policy and Medicine Compliance Update June 2023 Issue Features Update on Precision Lens Kickback Case, Novo Nordisk Legal Issues, Good RX FTC Case, and AI Compliance – Policy & Medicine Home Anti Kickback Policy and Medicine…

MIT’s School of Engineering and global health care company Novo Nordisk has announced the launch of a multi-year program to support postdoctoral fellows conducting research at the intersection of artificial intelligence and data science with life sciences. The MIT-Novo Nordisk Artificial Intelligence Postdoctoral Fellows Program will welcome its first cohort of up to 10 postdocs…

Policy and Medicine Compliance Update is our monthly compliance publication designed to help compliance professionals go in depth in issues and stay up to date on the latest trends.   We encourage you to subscribe to our monthly publication Policy an

Based on combinations of disease codes and the timing of their occurrence, the model was able to predict which patients are likely to develop pancreatic cancer in the future. Notably, many of the symptoms and disease codes were not directly related to or stemming from the pancreas. …

AI Revolution In Biotech No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal with very controlled environments, pure compounds, etc. Biology has to contend with preexisting extremely complex…

(Bloomberg) -- Blackstone Inc. is trying to curb rising employee health costs with an AI-powered individualized approach to diabetes to reduce people’s reliance on costly new drugs. Early results are promising. The private equity giant is testing a program from startup Twin Health with workers across 14 of its portfolio companies. The app is designed…